Eesti - eesti - Ravimiamet

glaxosmithkline trading services limited - amoksitsilliin+klavulaanhape - suukaudse suspensiooni pulber - 80mg+11,4mg 1ml 35ml 1tk; 80mg+11,4mg 1ml 140ml 1tk

Eesti - eesti - Ravimiamet

first pharma oÜ - amoksitsilliin+klavulaanhape - suukaudse suspensiooni pulber - 80mg+11,4mg 1ml 70ml 1tk; 80mg+11,4mg 1ml 140ml 1tk

Eesti - eesti - Ravimiamet

first pharma oÜ - amoksitsilliin+klavulaanhape - suukaudse suspensiooni pulber - 80mg+11,4mg 1ml 70ml 1tk; 80mg+11,4mg 1ml 140ml 1tk

Eesti - eesti - Ravimiamet

medochemie limited - amoksitsilliin+klavulaanhape - suukaudse suspensiooni pulber - 80mg+11,4mg 1ml 70ml 1tk; 80mg+11,4mg 1ml 140ml 1tk

Eesti - eesti - Ravimiamet

glaxosmithkline (ireland) limited - amoksitsilliin+klavulaanhape - suukaudse suspensiooni pulber - 80mg+11,4mg 1ml 70ml 1tk

Eesti - eesti - Ravimiamet

oÜ baxter estonia - aminohapped+naatriumkloriid+kaltsiumkloriiddihüdraat+magneesiumkloriidheksahüdraat+naatriumlaktaat - peritoneaaldialüüsilahus - 11,2g+5,38g+0,184g+0,051g+4,48g 1l 2l 4tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - amoksitsilliin+klavulaanhape - suukaudse suspensiooni pulber - 80mg+11,4mg 1ml 35ml 1tk; 80mg+11,4mg 1ml 140ml 1tk

Eesti - eesti - Ravimiamet

first pharma oÜ - amoksitsilliin+klavulaanhape - suukaudse suspensiooni pulber - 80mg+11,4mg 1ml 140ml 1tk; 80mg+11,4mg 1ml 70ml 1tk; 80mg+11,4mg 1ml 35ml 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Eesti - eesti - Ravimiamet

ideal trade links uab - amoksitsilliin+klavulaanhape - suukaudse suspensiooni pulber - 80mg+11,4mg 1ml 70ml 1tk